needham progen presentation : link, page-4

One would think that this is a particular good time to top up while PGL can be bought in the $5.11/14 range.

What has changed recently to make this a worse investment than at the beginning of this year?

The science is on track.
The company is loaded up with cash – about $100MM.
They are also going for phase3 in the near future.
They are gearing up (FDA manufacturing approval / new hire) to become an international pharmaceutical company with a blockbuster drug against some real serious cancer indications.

Today is the last day for acceptance of the entitlement issue. With the end of the tax year around the corner, there is still a possibility for more share price turbulence over the next couple of weeks. Then what?

A few solid company announcements – like;

* SPA approval by FDA,
* CRO appointment,
* Phase3 commencement,
* NSCLC data,
* Melanoma update,
* Prostate update,
* Naming of a regional partner for liver,
* Orphan drug status approval for liver. etc.,

Some of these pending announcement will re-evaluate Progen and should change the outlook IMHO.

As always own DD etc. required. This is not investment advice. Holding and topping up atm.